Jacobs Levy Equity Management, Inc Nuvation Bio Inc. Transaction History

Jacobs Levy Equity Management, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.58 - $3.69 $1.37 Million - $1.97 Million	532,583 Added 71.13%	1,281,376 $3.74 Million
Q1 2024 May 15, 2024	BUY	$1.46 - $3.97 $784,478 - $2.13 Million	537,314 Added 254.07%	748,793 $2.73 Million
Q4 2023 Feb 14, 2024	SELL	$0.96 - $1.53 $525,756 - $837,924	-547,663 Reduced 72.14%	211,479 $319,000
Q3 2023 Nov 16, 2023	BUY	$1.26 - $2.1 $308,143 - $513,571	244,558 Added 47.53%	759,142 $1.02 Million
Q2 2023 Aug 14, 2023	BUY	$1.56 - $1.84 $671,043 - $791,487	430,156 Added 509.49%	514,584 $926,000
Q1 2023 May 15, 2023	BUY	$1.6 - $2.48 $135,084 - $209,381	84,428 New	84,428 $140,000

158

157M

3.2K

98.7K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $613M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.